Prof Jay Suntharalingam and Dr Gerry Coghlan join the Clinical Excellence in Respiratory Care speakers to discuss pulmonary ...

Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

Pulmonary arterial hypertension is a devastating disorder characterized by precapillary pulmonary hypertension not caused by respiratory disease, obstruction of the pulmonary arteries, or certain less ...

PAH incidence and prevalence have increased globally, with significant regional disparities influenced by sociodemographic factors and healthcare access. High-SDI countries show stable ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Pulmonary hypertension in kidney transplant recipients is associated with lower graft and patient survival. Pre-existing pulmonary hypertension in kidney transplant recipients (PHTN) is associated ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Lindsay talks about the difficult road of managing a pulmonary arterial hypertension diagnosis, and how a newly discovered medication helped secure her future.